ribosomal protein S4X pseudogene 4Genealiases: RPS4P4 · RPS4X_1_17
Q-omics provides the consensus-scored RPS4XP4 profile across patient tissues and cancer cell-line models. RPS4XP4 expression is associated with patient survival in 20 of 34 cancer types, with the highest sampling consensus in KICH. Among the 18 cancer types available for tumor–normal comparison, RPS4XP4 is differentially expressed in 4, with the highest sampling consensus in PAAD. Additionally, RPS4XP4 RNA expression shows 5,471 significant pathway-activity associations, with the highest sampling consensus in KIRC. Together, these results highlight KICH, PAAD, and KIRC as cancer lineages where RPS4XP4 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPS4XP4 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPS4XP4 survival associations across molecular data types. RPS4XP4 RNA expression shows survival associations in the most cancer types (20). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPS4XP4 RNA expression–survival associations across cancer types. High RPS4XP4 expression shows unfavorable associations in KICH, LUSC, LIHC and KIRP, but favorable associations in UCS and READ. The KICH Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p = .001). Together, the overview and detailed table identify KICH as the clearest survival context for RPS4XP4 RNA expression.
This table summarizes RPS4XP4 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 4. The strongest signals are observed in PAAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPS4XP4. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPS4XP4 shows higher tumor expression in PAAD, COAD, KICH and LIHC. The PAAD box plot shows higher RPS4XP4 RNA expression in tumor versus normal tissue (log2 FC = +0.165, t-test p = .022).
This table shows molecular features associated with RPS4XP4 in patient tissues and cancer cell lines. In patient samples, RPS4XP4 shows the broadest associations at the RNA and protein expression levels, with KIRC recurring as the lineage with the largest associated feature set.
